LianBio CEO Yizhe Wang resigns; Adam Stone named interim CEO; Board to update on strategic review in Q1 2024

LianBio

CEO Yizhe Wang resigned effective Dec 16, 2023; receives severance of $1,525,000 plus accelerated vesting.
Board appoints Adam Stone (Perceptive Advisors CIO) as interim CEO; no compensation for service.
Board evaluating strategic alternatives; expects to communicate update in Q1 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Yizhe Wang

Chief Executive Officer

LIANY · LianBio

Effective: 2023-12-16
Successor: Adam Stone
Filed: December 19, 2023, 6:59 PM ET

Yizhe Wang, the Company’s Chief Executive Officer and member of the Company’s board of directors (the “Board”), has decided to resign as Chief Executive Officer and as a member of the Board, effective December 16, 2023, to pursue other business and professional interests and opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yizhe Wang resigned as Chief Executive Officer at LianBio.

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Yizhe Wang, the Company’s Chief Executive Officer and member of the Company’s board of directors (the “Board”), has decided to resign as Chief Executive Officer and as a member of the Board, effective December 16, 2023, to pursue other business and professional interests and opportunities.

View on SEC.gov

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.